Literature DB >> 18433749

The serine phosphorylation hypothesis of polycystic ovary syndrome: a unifying mechanism for hyperandrogenemia and insulin resistance.

Andrew A Bremer1, Walter L Miller.   

Abstract

Polycystic ovary syndrome (PCOS) is a common endocrinopathy affecting 4%-8% of reproductive-aged women. The syndrome is characterized by hyperandrogenemia and disordered gonadotropin secretion and is often associated with insulin resistance. However, rather than being one disease entity caused by a single molecular defect, PCOS under its current diagnostic criteria most likely includes a number of distinct disease processes with similar clinical phenotypes but different pathophysiologic mechanisms. The serine phosphorylation hypothesis can potentially explain two major features of PCOS--hyperandrogenemia and insulin resistance. Further defining the molecular mechanisms regulating androgen biosynthesis and insulin action in PCOS patients will permit a better understanding of the syndrome and may lead to the generation of novel specific pharmacologic therapies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18433749     DOI: 10.1016/j.fertnstert.2008.02.091

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  25 in total

Review 1.  The biology of gonadotroph regulation.

Authors:  Nick A Ciccone; Ursula B Kaiser
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2009-08       Impact factor: 3.243

Review 2.  Polycystic ovary syndrome throughout a woman's life.

Authors:  José Bellver; Luis Rodríguez-Tabernero; Ana Robles; Elkin Muñoz; Francisca Martínez; José Landeras; Juan García-Velasco; Juan Fontes; Mónica Álvarez; Claudio Álvarez; Belén Acevedo
Journal:  J Assist Reprod Genet       Date:  2017-09-27       Impact factor: 3.412

3.  Preliminary data on effects of metformin on PED/PEA-15 cellular levels in obese women with polycystic ovary syndrome.

Authors:  S Savastano; R Valentino; G Pizza; A De Rosa; F Orio; F Passaretti; P Formisano; G Lombardi; F Beguinot; A Colao
Journal:  J Endocrinol Invest       Date:  2010 Jul-Aug       Impact factor: 4.256

4.  Phosphorylation of human cytochrome P450c17 by p38α selectively increases 17,20 lyase activity and androgen biosynthesis.

Authors:  Meng Kian Tee; Walter L Miller
Journal:  J Biol Chem       Date:  2013-07-08       Impact factor: 5.157

Review 5.  Disordered follicle development.

Authors:  R Jeffrey Chang; Heidi Cook-Andersen
Journal:  Mol Cell Endocrinol       Date:  2012-07-31       Impact factor: 4.102

Review 6.  Polycystic ovary syndrome in the pediatric population.

Authors:  Andrew A Bremer
Journal:  Metab Syndr Relat Disord       Date:  2010-10       Impact factor: 1.894

Review 7.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

8.  In polycystic ovary syndrome, adrenal steroids are regulated differently in the morning versus in response to nutrient intake.

Authors:  Dumindra Gurusinghe; Sharan Gill; Rogelio U Almario; Jennifer Lee; William F Horn; Nancy L Keim; Kyoungmi Kim; Sidika E Karakas
Journal:  Fertil Steril       Date:  2009-04-01       Impact factor: 7.329

9.  Evaluation of the relationship between serum ferritin and insulin resistance and visceral adiposity index (VAI) in women with polycystic ovary syndrome.

Authors:  Büşra Başar Gökcen; Yasemin Akdevelioğlu; Sultan Canan; Nuray Bozkurt
Journal:  Eat Weight Disord       Date:  2020-08-08       Impact factor: 4.652

10.  Metabolomic Profiling of Pregnancies With Polycystic Ovary Syndrome Identifies a Unique Metabolic Signature and Potential Predictive Biomarkers of Low Birth Weight.

Authors:  Ilhame Diboun; Manjunath Ramanjaneya; Lina Ahmed; Mohammed Bashir; Alexandra E Butler; Omar Albagha; Abdul Badi Abou-Samra; Stephen L Atkin; Nayef A Mazloum; Mohamed A Elrayess
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-15       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.